# Cofactor Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cofactor-genomics

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.cofactorgenomics.com
- Total disclosed funding: $11M
- Latest round: Series A (Jun 14, 2017)
- Investors on record: 8

## About

Founded in 2008 by Jarret Glasscock (CEO) and based in Missouri, US, Cofactor Genomics, Inc. operates as a medical diagnostic company that predicts patient response to immunotherapy. In December 2025, Cofactor Genomics, Inc. raised USD 4.48 million in venture funding from new investor LabCorp Ventures, with participation from returning investor Ascension Ventures.

The firm develops and offers a genome predictive platform that uses RNA sequencing and predictive diagnostic services to identify the subset of patients who respond better to immunotherapy treatments. The firm combines machine-learning based predictive immune modelling approach and RNA from FFPE solid tumor specimens to help multidimensional biomarkers to better capture the complex immune response at the site of a tumor.

The company will use the December 2025 funding to support the further development of its immunotherapy and expansion plans initiatives.

## Funding rounds

- Series A, Jun 14, 2017, $11M — Menlo Ventures, Ascension Ventures, Stanford University, Y Combinator, Wilson Sonsini Goodrich & Rosati, DCVC, iSelect Fund Management, Argonautic Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series A
- Stanford University — Series A
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Series A
- Wilson Sonsini Goodrich & Rosati — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- iSelect Fund Management (https://capitalatlas.ai/funds/iselect-fund-management) — Series A
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A